CAPR Stock Price, News, Filings & Events — Caprock Mining Corp

I couldn’t find credible evidence that there's a company with ticker “CAPR” listed on the Canadian Securities Exchange (CSE) with the business profile you asked about. Instead, “CAPR” matches Capricor Therapeutics, Inc., which is a U.S.-based biotech company trading on the Nasdaq , not CSE. (sec.gov) --- Here’s what Capricor Therapeutics actually does: - Capricor Therapeutics is a clinical-stage biotech firm focused on developing cell- and exosome-based therapies for rare diseases, especially Duchenne muscular dystrophy (DMD) and other conditions with little or no existing treatments. Their main product is Deramiocel (also known as CAP-1002), an allogeneic cardiosphere-derived cell therapy. (sec.gov) - They also invest in exosome technology, including developing engineered exosomes that can deliver RNA, proteins, or small molecule therapeutics. Some work includes vaccine development (e.g., for SARS-CoV-2) and other therapeutic uses during preclinical and early clinical stages. (stockanalysis.com) --- How they get paid and what their business model looks like: - As a biotech company not yet having commercial products, revenue comes from grants , collaborations , license agreements , strategic partnerships , and potentially milestone payments from regulatory or developmental achievements. They have received funding from governmental bodies like NIH and others. (sec.gov) - They bear high R&D and regulatory costs, since their therapies are in development or under review. Capricor must support clinical trials, manufacturing development (CMC), quality control, and regulatory f...

The most recent material news for CAPR.CSE includes the following items: 1. CAPR Investors Have Opportunity to Lead Capricor Therapeutics, Inc. Securities Fraud Lawsuit with SBS Law (September 7, 2026) - This news highlights a class action lawsuit against Capricor Therapeutics, Inc. for alleged violations of the Securities Exchange Act. Shareholders who purchased shares during the specified class period are encouraged to contact the law firm regarding potential lead plaintiff appointments. This matters for shareholders as it could lead to compensation for losses incurred if the lawsuit is successful. 2. CAPR IMPORTANT DEADLINE: ROSEN, LEADING TRIAL ATTORNEYS, Encourages Capricor Therapeutics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action - CAPR (September 6, 2026) - Similar to the previous news, this announcement emphasizes the importance of a deadline for investors who suffered significant losses to join the class action lawsuit. The urgency of the September 28, 2026 deadline is crucial for shareholders as it may affect their ability to seek compensation. 3. CAPR CLASS ACTION NOTICE: Faruqi & Faruqi, LLP Reminds Capricor Investors of Securities Class Action Lawsuit Deadline on September 28, 2026 (August 30, 2026) - This notice reiterates the ongoing class action lawsuit and encourages investors to discuss their legal rights. The involvement of multiple law firms indicates a serious concern regarding the company's compliance with securities laws, which could impact investor confidence and the stock pr...

The bull case for CAPR.CSE (Caprock Mining Corp) is as follows: - Potential for Legal Recovery : Recent news indicates that investors in Capricor Therapeutics, Inc. (NASDAQ: CAPR) are encouraged to join class action lawsuits due to potential securities fraud. If successful, this could lead to financial recovery for affected investors, enhancing overall market sentiment towards the company. - Upcoming Events : The upcoming event titled "Defining a Sizeable Resource in Quebec’s World-Class Gold Belt" on September 16, 2026, could provide insights into Caprock Mining's resource potential, attracting investor interest and potentially leading to positive stock movement. - Market Positioning : Caprock Mining operates in a lucrative sector, with gold being a sought-after commodity. The focus on Quebec’s gold belt positions the company strategically within a region known for its rich mineral resources. - Investor Engagement : The ongoing class action lawsuits and legal discussions surrounding Capricor Therapeutics may increase investor engagement and awareness of Caprock Mining, potentially leading to a broader investor base and increased trading volume. - Resource Development Potential : If Caprock Mining can successfully define and develop its resources, it could lead to significant revenue generation, especially in a favorable market for gold and mining operations. - Strategic Management Insights : The participation of key personnel, such as Daniel Cohen (Executive Chairman) and Vishal Gupta (President & CEO), in public events suggests a proactive approach to investor relation...

The bear case for CAPR.CSE (Caprock Mining Corp) includes the following risks: - Legal Risks : CAPR is currently associated with a class action lawsuit against Capricor Therapeutics, Inc. for securities fraud, which could lead to financial liabilities and damage to reputation. Investors should monitor the developments of this lawsuit closely. - Market Volatility : The mining sector is often subject to significant price fluctuations based on commodity prices, regulatory changes, and market demand. A downturn in gold prices could adversely affect CAPR's financial performance. - Operational Risks : As a mining company, CAPR faces risks related to exploration, extraction, and operational efficiency. Any delays or failures in these areas could impact production and profitability. - Funding Challenges : Mining projects often require substantial capital investment. If CAPR struggles to secure funding for its operations or expansion, it may hinder growth prospects and operational capabilities. - Regulatory Environment : Changes in mining regulations or environmental policies could impose additional costs or operational restrictions on CAPR, affecting its ability to operate effectively. - Management Uncertainty : The company profile does not provide information on management, which raises concerns about leadership stability and strategic direction. Lack of transparency in management could lead to investor skepticism.

Here are the main upcoming catalysts for Capricor Therapeutics (Ticker: CAPR on Nasdaq; not confirmed as CAPR.CSE) over the next 6-12 months. These are likely to have major impact on valuation, regulatory status, and commercialization potential. --- Key Upcoming Catalysts & Timing | Catalyst | What to Watch For | Approximate Timing | |----------|-------------------|---------------------| | FDA decision on Deramiocel’s BLA | The Company submitted a “major amendment” with new 24-month HOPE-3 trial data and clarified indication (upper limb function). The FDA pushed the PDUFA target action date back by 3 months to November 22, 2026, to allow review of that data. (sec.gov) | November 22, 2026 (Target PDUFA date) (sec.gov) | | Earnings / Financial Reports | Q3 2026 earnings will give updated cash runway, expense guidance, and possibly early hints at commercial readiness. Historically reported in mid-November. (tipranks.com) | Estimated: November 9–17, 2026 (marketchameleon.com) | | StealthX™ vaccine trial final data | From the NIAID‐sponsored Phase 1 trial, completion of safety data + immune response (including cellular immunity) expected. Could trigger a funded Phase 2 if criteria are met. (capricor.com) | Later in 2026 (capricor.com) | | Commercial readiness preparations | Construction/validation of GMP manufacturing expansion in San Diego (2nd floor). Hiring of commercial leadership (new CCO) and market access, reimbursement planning. These prepare for launch if approval is received. (sec.gov) | Ongoing now; material events likely in late 2026 through early 2027. | | Distri...

I couldn’t find credible evidence of a company called “CAPR” listed on the Canadian Securities Exchange (CSE) that matches your description. The ticker “CAPR” more reliably corresponds to Capricor Therapeutics, Inc. , trading on NASDAQ (symbol: CAPR), a U.S.-based biotech firm. (capricor.com) Assuming you meant Capricor Therapeutics (NASDAQ: CAPR) , here’s a summary based on their most recent (Q2 2026) earnings call and investor update: --- What Management Emphasized - Regulatory Path Forward & Data Strength Capricor is focused on securing approval for its lead product, Deramiocel (CAP-1002), for Duchenne muscular dystrophy (DMD). Management emphasized that while an FDA advisory committee voted 3-in-favor vs. 9-against on the cardiomyopathy indication, the committee was not asked to vote on the primary HOPE-3 skeletal muscle (upper limb) endpoint, which achieved statistical significance (p = 0.029). (sec.gov) - Amended BLA & Indication Strategy They plan to submit a BLA amendment focusing on the upper limb skeletal muscle indication—essentially realigning their regulatory request with what the HOPE-3 data most strongly supports. This amendment is expected to impact the PDUFA action date. (fool.com) - Publication & Peer Review The full HOPE-3 Phase 3 dataset was published in The Lancet , which management portrayed as an important validation, including a correction of a statistical model for left ventricular ejection fraction (LVEF) (previously reported as p = 0.04 but corrected to p = 0.09) for the entire group. The cardiomyopathy subgroup LVEF remained nominally signific...